) is a new, compact, inhaler device containing the same aerosol canister as a conventional metered dose inhaler (MDI). However, the design of the Spacehaler has been shown to reduce the velocity of the aerosol, thus reducing the proportion of non-respirable particles delivered to the patient. This study compared radioaerosol deposition patterns following inhalation of 250 g of beclomethasone dipropionate from the Spacehaler and a conventional MDI (Beclazone , Norton Health Care, Harlow, U.K.). After rigorous in vitro validation of the radiolabelling technique, 12 asthmatic subjects (seven men aged 20-69 years, mean baseline FEV 1 2·59 l ( 0·55 l) received one dose of 99m Tc-labelled beclomethasone dipropionate 250 g via either a Spacehaler or MDI on each of two study days in a randomized cross-over manner. All subjects had been taught the required inhalation technique before the dose was administered. Inhalation details were recorded using a spirometer connected in series with the device. Lung and oropharyngeal depositions were measured by gamma scintigraphy.
Introduction
The metered dose inhaler (MDI) has been the mainstay of asthma management for the last 30 years. The concept of delivering a small dose of drug directly to the airways is logical, and the MDI is cheap and convenient (1) . However, there are some problems with MDI use. Firstly, the characteristics of the aerosol mean that a dose of drug is emitted from the MDI at high speed (typically 30 m s 1 ) containing a large proportion of particles that are more than 5 m in diameter (2) . Most of these particles (representing up to 80% of the dose) impact on the oropharynx and are swallowed (3) which may, particularly with inhaled corticosteroids, contribute to oral and systemic side-effects. Secondly, the devices are not easy to use. Many patients have difficulty coordinating actuation and inhalation, and a significant proportion are unable to continue to inhale through the mouth when the aerosol is released into the oropharynx (the 'cold-Freon effect') (4) .
A number of different inhaler devices have been developed to overcome the problems of the MDI. Dry powder inhalers may be relatively expensive and may not reduce oropharyngeal deposition (5) . Large volume spacer devices reduce the velocity of the aerosol and the amount of drug deposited in the oropharynx (6) but are bulky and cumbersome. The Spacehaler (Evans Medical Ltd, Leatherhead, U.K.) (previously known as the Gentlehaler ) (7) is a new, compact pressurized aerosol device that uses the same canister as a conventional metered dose inhaler. Its design however, reduces the velocity of the aerosol cloud that emerges from the inhaler from 30 to 2 m s 1 and retains the majority of the non-respirable fraction of the emitted dose (8) . The Spacehaler has been shown to produce clinically equivalent bronchodilator effects to a standard MDI plus spacer when used to deliver 200 g salbutamol, and to be preferred by patients (9) . Current U.K. guidelines on asthma management (10) advise that patients receiving inhaled steroids via a MDI at a dose of more than 800 g beclomethasone dipropionate (BDP) or equivalent per day should use a large volume spacer device in order to reduce the risk of local and systemic effects. However, there is little published work comparing the deposition characteristics of BDP delivered via the MDI with the large volume spacer in vivo. One study has shown that use of a large volume spacer significantly increased the percentage of a dose of BDP 250 g delivered to the lungs compared with the MDI alone (11) . The current study has been performed in order to compare the deposition of a single shot of BDP 250 g administered via a Spacehaler and conventional MDI in asthmatic subjects.
Methods

SPACEHALER DEVICE
The Spacehaler is a compact (7·5 cm long) low-velocity pressurized aerosol device. It uses the same canister as a conventional MDI, but incorporates a vortex chamber immediately upstream of the nozzle, together with a narrow air inlet in the rear and a bell-shaped internal surface in the mouthpiece (Fig. 1) . The effect is to reduce the velocity of the spray and to retain most of the non-respirable particles within the actuator.
SUBJECTS
Twelve non-smoking asthmatic subjects (seven men) received study medication [age range 20-69 years; mean baseline forced expiratory volume in 1 s (FEV 1 ) 2·59 l ( 0·55 l)]. A further two subjects entered the study but were withdrawn before receiving treatment due to adverse events (upper respiratory tract infection and acute exacerbation of asthma). All subjects gave written informed consent. All had a clinical diagnosis of asthma which had been confirmed by reversibility testing with an inhaled -agonist. They remained on their normal asthma medication throughout the study. Each subject was only dosed on a given study day providing their FEV 1 was within 15% of its value at the pre-study screen.
STUDY DESIGN
This was a single centre, randomized, cross-over study. Subjects who satisfied the entry criteria attended the centre on two occasions, not less than 44 h apart. At each of these visits they received a single dose of BDP (250 g per inhalation) delivered either via the Spacehaler or a conventional MDI, in a random order. The inhalation mode was standardized for each dosage regimen and subjects were taught the required technique using a placebo device. Subjects were instructed to empty their lungs before taking a slow deep inhalation. The investigator fired the device approximately 1 s after the beginning of inhalation. At the end of the inhalation a 10-s breath holding pause was observed before the subject breathed out through a filter to trap any radioactive aerosol in the expired air. During the aerosol inhalations, the inhaled volume, inhaled flow rate and breath holding pause were recorded by a Vitalograph MDI-Compact spirometer connected in series with the inhaler. The addition of this connector does not change the particle size of the spray.
Deposition patterns in the lungs and oropharynx were determined by gamma scintigraphy recorded immediately following administration of the radiolabelled aerosol. Four views were recorded: posterior chest; anterior chest; right lateral oropharynx; and actuator/exhalation filter. Radioactivity in the stomach and oesophagus was assumed to have been deposited in the oropharynx. The amount of radiolabel in the inhalers was adjusted so that the total amount of radioactivity delivered did not exceed 10 MBq 99m Tc per metered dose. On one of the study days, unless they had previously taken part in such an examination during the previous two years, subjects underwent a posterior lung ventilation scan using the inert gas 
RADIOLABELLING VALIDATION
Before comparing the in vivo lung deposition from the Spacehaler and pressurized MDI (Beclazone , Norton Health Care Ltd, Harlow, U.K.) it was first necessary to develop and validate a radiolabelling method to ensure that the radiolabel acted as an accurate marker of drug distribution within the aerosol cloud. In vitro tests were carried out using the High Precision Multi-stage Liquid Impinger (HPMLI), which has an initial glass 90 bend (throat) and four impaction stages. At a flow rate of 60 l min 1 , particles between 3·1 and 6·8 m in diameter are collected in stage 3 and particles with a diameter of less than 3·1 m are collected in stage 4. Particles deposited in stages 3 and 4 therefore constitute the fine particle fraction.
Determination of particle size of marketed BDP
MDIs delivering BDP 250 g per metered dose (Beclazone , Norton Health Care, Harlow, U.K.) were shaken in an ultrasonic bath to mix the formulation thoroughly and then primed by firing 10 shots to waste. These canisters were designated 'unlabelled MDIs'. The particle size distribution IMPROVED TARGETING OF BDP WITH SPACEHALER from these canisters was determined by firing the canister 40 times (shaken between each shot) into the HPMLI at a continuous airflow of 60 l min 1 . Each stage of the apparatus was washed out with methanol 50 ml and the washings assayed using ultraviolet analysis to determine the concentration of BDP in each solution. The percentage distribution of BDP was calculated as the mass of drug recovered from each stage of the HPMLI divided by the total mass of drug recovered.
Determination of particle size distribution of radiolabelled BDP
MDIs were labelled using an adaptation of the method described by Köhler et al. (12) . MDIs containing radiolabel ( 99m Tc pertechnetate), BDP suspension and an additional 0·2 ml CFC-11 propellant were prepared using empty canisters and metering valves. These inhalers (designated 'labelled MDIs') were checked for leaks, and were mixed and primed, before shots were fired into the HPMLI. Washings from the HPLMI stages were taken and the quantity of radiolabel in each stage was determined using a gamma camera. The percentage distribution of drug was also measured by ultraviolet analysis.
In addition, to ensure that process of manufacturing the labelled MDIs did not affect the particle size of the drug, a further set of MDIs were prepared to the same method but without the addition of radiolabel ('CFC-added MDIs'). The particle size distribution of these inhalers was measured by ultraviolet analysis.
DATA ANALYSIS
The lung outlines from the 81m Kr ventilation scan were used to define the perimeters of the lung fields on the aerosol views. The lungs were divided into central, intermediate and peripheral regions of interest (13) . The peripheral lung zone/central lung zone deposition ratio (lung penetration index) was calculated. Regions of interest were also drawn around the oropharynx, oesophagus and stomach. The counts obtained within these regions were corrected for background radioactivity, radioactive decay and tissue attenuation (14) . In regions where both anterior and posterior images were recorded, the geometric mean of counts in both images was calculated. Determination of the percentage of the dose deposited in the oropharynx included activity adhering to the mouth and pharynx together with any swallowed activity detected in the oesophagus, stomach and intestine. The counts for each area were expressed as a percentage of the metered dose, which was determined from the sum of the total body counts in addition to those deposited on the actuator and the exhalation filter.
STATISTICS
The Wilcoxon matched-pairs signed-ranks test was used to determine whether differences between the deposition patterns for the two devices were significant. A P-value of c0·05 was considered significant.
Results
VALIDATION OF RADIOLABELLING TECHNIQUE
As can be seen from Table 1 , this modified Köhler method provides an acceptable means of radiolabelling BDP and provides particle size data comparable with those from unlabelled BDP inhalers. The ratio of the radiolabel fine particle fraction to the fine particle fraction from the unlabelled MDI was 1·06. 
LUNG FUNCTION AND INHALATION DETAILS
Baseline lung function was similar on both study days: mean baseline FEV 1 was 2·66 l ( 0·55 l) before the Spacehaler and 2·63 l ( 0·54 l) before the MDI. Inhalation details for each subject are shown in Tables 2  and 3 . Subject 4 failed to record an inhalation for the Spacehaler as a result of activating the spirometer whilst sealing her lips around the device. Four subjects (numbers 4, 5, 10 and 14) paused during inhalation from the MDI when the device was fired. All of the subjects continued inhalation after this brief pause but the spirometer stopped recording the inhalation at the time of the pause.
DEPOSITION PATTERNS
Deposition data for BDP delivered via the Spacehaler and the MDI are shown in Table 4 . The mean () whole lung deposition was 23·0% (8·3%) and 12·8% (6·8%) for the Spacehaler and the MDI, respectively. Individual whole lung deposition values are shown in Fig. 2 3·26  28·8  12·7  04  NR  NR  NR  NR  05  NR  NR  NR  NR  06  4·1  2·75  40·2  10·5  07  5·3  3·13  35·4  9·9  08  8·4  2·48  17·7  10·4  09  4·2  2·00  28·6  12·6  10  NR  NR  NR  NR  11  3·3  2·20  40·0  14·8  12  4·4  1·73  23·6  9·7  13  6·1  2·02  19·9  17·0  14  NR  NR  NR  NR   Mean  5·3  2·45  29·3  12·2    1·7  0·56  8·7  2·6  n  8  8  8  8 NR, Not registered.
IMPROVED TARGETING OF BDP WITH SPACEHALER
deposition of BDP was significantly greater with the Spacehaler than the MDI (P<0·01). There was a trend towards a lower mean peripheral/mean central zone deposition ratio with the Spacehaler although this did not reach statistical significance.
Mean oropharyngeal deposition was significantly lower for the Spacehaler (27·9%) than the MDI (73·6%). A significantly larger proportion of the metered dose was deposited on the Spacehaler than on the MDI (mean values 48·0 and 12·4%). The mean percentage of the dose captured on the exhalation filter for both the Spacehaler and the MDI was similar (1·1 and 1·2%, respectively). Fig. 3 shows typical scintigraphic images obtained during the study.
SAFETY
Several subjects had small falls in FEV 1 (<11% of baseline) during the study days. Four subjects (numbers 1, 6, 9 and 13) experienced a fall in FEV 1 after using both the Spacehaler and the MDI. One subject (number 5) experienced a fall in FEV 1 only after using the Spacehaler . One serious adverse event was reported during the study. Subject 7 experienced a fall in FEV 1 of 29% 30 min after using the MDI, which responded to bronchodilator treatment. Later that day, the subject developed symptoms of an upper respiratory tract infection and an acute exacerbation of asthma, which was treated with a short course of oral steroids and resolved without sequelae.
Discussion
The radiolabelling method used in this study [modified from the method described by Köhler et al. (12) ] was extensively validated in vitro before being used in vivo: the validation process confirmed that the radiolabel did not alter the particle size distribution of BDP and was an accurate marker for the drug. The original method described by Köhler et al. has been shown to alter the characteristics of the aerosol in favour of large sized particles compared with the unlabelled product (15) . This improvement on the original Köhler et al. method described in this study represents a significant advance in MDI radiolabelling strategies. The in vivo radionuclide distributions measured by the gamma camera can therefore be taken as a true reflection of the distribution of BDP both in the body and on the devices used in the study.
The mean whole lung deposition for the MDI was 12·8% of the metered dose, compared with 23·0% for the Spacehaler . These results contrast with the findings of a previous scintigraphic study (8) , which gave similar values for whole lung depositions of salbutamol (100 g per actuation) for the Spacehaler and MDI (19·9 and 18·8%, respectively). This discrepancy may arise from the way in which patients in this study reacted to the fast and slow moving sprays emerging from the MDI and Spacehaler respectively. Spray from the Spacehaler travels at a velocity <2 m s 1 . Patients may find it easier to inhale this spray deeply into the lungs than the spray from the MDI which travels at an initial velocity of <30 m s 1 . In the present study, lung deposition for the Spacehaler was close to the value seen in the previous study (8) while lung deposition for the MDI was lower. Some of the discrepancy may represent unusually poor performance with the MDI.
Evidence from this study lends weight to this argument. Despite a lengthy practice session immediately before dosing, several subjects displayed a momentary pause in inhalation just after actuation of the MDI, presumably as the aerosol spray hit the back of the throat. This is the so-called 'cold Freon' effect related to the cooling of the spray as propellants evaporate, and also perhaps to the presence of large particles (<10 m) emitted from the MDI. The effect was to stop the MDI Compact spirometer recording even though the subject continued the inhalation. It is possible that the problems the four subjects experienced in using the MDI could have lowered the mean whole lung deposition value for the whole group, although this does not appear to have been the case. Of the four inhalations affected in this manner, two subjects had deposition values below the average for the group, whilst two had deposition values above the average for the group. The mean whole lung deposition value for this sub-group was 13·6%, which was similar to that obtained for the whole group (12·8%). In addition, the values for mean whole lung deposition for the eight subjects with perfect technique for both devices were 20·6% ( 8·3%) for the Spacehaler and 12·3% ( 7·0%) for the MDI; values which are very similar to those for the full set of 12 subjects.
Two pharmacokinetic studies support the finding of higher lung deposition for the Spacehaler compared to the MDI. One showed significantly higher levels plasma levels of salbutamol in healthy volunteers during the first 60 min after inhalation from an early prototype of the Spacehaler than from the MDI (16) . Whether these subjects had any problems using the MDI is not known, although it is our experience that healthy volunteers who do not use MDI regularly are more likely than asthmatic patients to exhibit the cold-Freon effect when inhaling from this device. A second study (17) showed increased urinary excretion of mometasone furoate for an earlier prototype of the Spacehaler compared to the MDI, which was felt to be due to enhanced lung deposition of drug from the Spacehaler . Two other factors may help to explain the discrepancies between the various studies carried out to evaluate the Spacehaler . First, different drugs and doses were used in the two studies (salbutamol 100 g and beclomethasone 250 g); differences in formulation (propellant mixtures, propellant vapour pressures and plume geometries) make it difficult to extrapolate from one drug formulation to another. However, the lower deposition value for the MDI in the present study compared with that recorded in the previous study (8) may reflect the higher dose of drug per shot (250 g vs. 100 g). Previous scintigraphic data from MDIs have shown that lung deposition decreases as the mass of drug per metered dose increases (18, 19) . Second, the Spacehalers used in the two scintigraphic studies were not identical; the device used in the present study had two air inlet holes in the rear of the device, compared to only a single hole for the earlier version of the device used in the previous study. The single hole device had a very high resistance to airflow and patients could only achieve an average inhaled flow of 20 l min 1 with considerable inspiratory effort. In the present study, the resistance to airflow was much less and patients could generate the targeted inhaled flow of 30 l min 1 easier for patients to 'draw' the aerosol down into the lungs with the device used in the present study, which could explain why it performed better than the MDI. Further, the air inlet holes probably perform an important function in the formation of the low velocity cloud in the Spacehaler and it is possible that the spray kinetics of the Spacehaler devices used in the two scintigraphic studies differed as a consequence. Perhaps the slower aerosol stream from the Spacehaler optimizes lung deposition despite minor variations in inhaler technique which could adversely affect the performance of the standard MDI.
Oropharyngeal deposition for the Spacehaler was significantly lower than that for the MDI (27·9 and 73·6%, respectively). The low oropharyngeal deposition with the Spacehaler is likely to be due to two factors: 1. the function of the Spacehaler mouthpiece is such that it has drug delivery characteristics similar to those of a spacer, with a significant fraction of the dose being retained on the device itself; and 2. the relatively slow moving aerosol cloud reduces the inertial mass of the larger particles and enables a greater proportion of particles to remain entrained within the inhaled airstream, thus reducing impaction in the oropharynx. The difference in oropharyngeal deposition seen in this study is consistent with that observed in the earlier scintigraphic study (8) . The percentage of the dose in the exhaled air (i.e. trapped on the exhalation filter) was very low for both the Spacehaler and the MDI, and was in line with the findings of previous studies using MDIs (18) . The distribution of radiolabel within peripheral, intermediate and central lung zones broadly resembled those observed in the previous scintigraphic study with the Spacehaler (8) . The retention of up to 48% of the dose on the device itself does not appear to affect performance: in vitro work has confirmed that the deposition characteristics of the Spacehaler are consistent throughout the life of the inhaler. As a hygiene precaution, patients are advised to wash the device once a week.
In an ideal aerosol delivery system, drug delivery to the lungs would account for 100% of the dose delivered to the body with no drug being deposited in the oropharynx. The Spacehaler showed a considerable improvement in lung deposition expressed as a percentage of total body deposition (45·2%) when compared with the MDI (14·8%). This performance is similar to that seen with a large volume spacer device: in a study looking at lung deposition of BDP 250 g, a large volume spacer produced lung deposition (expressed as a percentage of total body deposition) of 48·7% compared with 17·4% for MDI alone (11) . The Spacehaler targets drug to the lungs better than a conventional MDI, and may be a suitable alternative to the large volume spacer devices recommended in U.K. asthma management guidelines for patients receiving high-dose BDP (10) .
On the basis of this study, the Spacehaler represents an improvement over conventional MDIs. It provides more efficient delivery of drug to the lungs, reduces the risk of local and systemic side-effects from oropharyngeal deposition and results in a lower total dose of drug being delivered to the patient.
